GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » ROE %

Tourmaline Bio (Tourmaline Bio) ROE % : 4.89% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Tourmaline Bio's annualized net income for the quarter that ended in Dec. 2023 was $8.50 Mil. Tourmaline Bio's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $173.96 Mil. Therefore, Tourmaline Bio's annualized ROE % for the quarter that ended in Dec. 2023 was 4.89%.

The historical rank and industry rank for Tourmaline Bio's ROE % or its related term are showing as below:

TRML' s ROE % Range Over the Past 10 Years
Min: -45.46   Med: -45.46   Max: -6.85
Current: -6.85

During the past 3 years, Tourmaline Bio's highest ROE % was -6.85%. The lowest was -45.46%. And the median was -45.46%.

TRML's ROE % is ranked better than
76.25% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs TRML: -6.85

Tourmaline Bio ROE % Historical Data

The historical data trend for Tourmaline Bio's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio ROE % Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
ROE %
- - -45.46

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial - Negative Equity - -55.93 4.89

Competitive Comparison of Tourmaline Bio's ROE %

For the Biotechnology subindustry, Tourmaline Bio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tourmaline Bio's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's ROE % distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's ROE % falls into.



Tourmaline Bio ROE % Calculation

Tourmaline Bio's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-42.124/( (-19.732+205.042)/ 2 )
=-42.124/92.655
=-45.46 %

Tourmaline Bio's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=8.504/( (142.874+205.042)/ 2 )
=8.504/173.958
=4.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Tourmaline Bio  (NAS:TRML) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=8.504/173.958
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(8.504 / 0)*(0 / 180.678)*(180.678 / 173.958)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0386
=ROA %*Equity Multiplier
=N/A %*1.0386
=4.89 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=8.504/173.958
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (8.504 / 8.504) * (8.504 / -25.268) * (-25.268 / 0) * (0 / 180.678) * (180.678 / 173.958)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -0.3366 * N/A % * 0 * 1.0386
=4.89 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Tourmaline Bio ROE % Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tourmaline Bio (Tourmaline Bio) Business Description

Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.